Diagnostic Value of Coagulation-Fibrinolysis Biomarkers for Metastasis in Lung, Ovarian, Breast, and Colorectal Cancers
Clinical and Applied Thrombosis/Hemostasis · 2026-01 · 32
DOI: 10.1177/10760296261438236 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, online erschienen am 29.05.2026. Verfasst von Yumei Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Human Genetic Resources, National Research Institute for Health and Family Planning, Beijing, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Fibrinolysis, Ovarian Neoplasms, Colorectal Neoplasms. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Dysregulation of the coagulation and fibrinolytic systems has been closely linked to cancer progression and metastasis. This study investigated whether the coagulation- and fibrinolysis-related biomarkers, TAT, PIC, TM, and tPAIC, are correlated with cancer metastasis.
Methods
Plasma levels of TAT, PIC, TM, and tPAIC were measured in 240 treatment-naive patients with lung, ovarian, breast, or colorectal cancer and 120 healthy individuals. Participants were categorized into metastasis, non-metastasis and healthy groups based on clinical evaluation and imaging results. Statistical analysis and ROC curves were used to assess the performance of individual and combined biomarkers in detecting metastasis.
Results
All four biomarkers were significantly elevated in patients with metastasis ( P < .001). In multivariate logistic regression analysis, PIC demonstrated the strongest association with metastasis. ROC curve analysis revealed that in lung cancer patients, a parallel test of TAT and PIC achieved a sensitivity of 93.33% and an NPV of 88.24%. In ovarian cancer, a serial test of TAT, PIC, and TM achieved a specificity of 80.00% and a PPV of 75.00%. In breast cancer, a parallel test of TAT, PIC, and tPAIC yielded a sensitivity of 93.33% and an NPV of 89.47%. In colorectal cancer, a parallel test of all four markers achieved a sensitivity of 96.67% and an NPV of 93.75%.
Conclusion
Distinct combinations of coagulation and fibrinolysis biomarkers demonstrate high diagnostic performance for detecting metastasis across different cancer types. Tailoring biomarker panels according to cancer type may provide significant clinical value in monitoring and predicting cancer metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Center for Human Genetic Resources, National Research Institute for Health and Family Planning, Beijing, China.
- Laboratory Department, Peking University International Hospital, Beijing, China.
ORCID-Profile: Yumei Zhao, Xinping Sun, Bozhi Lin, Shiyuan Xu, Huafang Gao
Zitieren
APA
Zhao, Y., Sun, X., Lin, B., Xu, S., & Gao, H. (2026). Diagnostic Value of Coagulation-Fibrinolysis Biomarkers for Metastasis in Lung, Ovarian, Breast, and Colorectal Cancers. Clinical and Applied Thrombosis/Hemostasis, 32. https://doi.org/10.1177/10760296261438236
Vancouver
Zhao Y, Sun X, Lin B, Xu S, Gao H. Diagnostic Value of Coagulation-Fibrinolysis Biomarkers for Metastasis in Lung, Ovarian, Breast, and Colorectal Cancers. Clinical and Applied Thrombosis/Hemostasis. 2026;32. doi:10.1177/10760296261438236
BibTeX
@article{Zhao2026,
author = {Zhao, Yumei and Sun, Xinping and Lin, Bozhi and Xu, Shiyuan and Gao, Huafang},
title = {Diagnostic Value of Coagulation-Fibrinolysis Biomarkers for Metastasis in Lung, Ovarian, Breast, and Colorectal Cancers},
journal = {Clinical and Applied Thrombosis/Hemostasis},
year = {2026},
volume = {32},
doi = {10.1177/10760296261438236}
}
EUVIMED